文献速递腹部泌尿生殖CTMR

LI-RADS CT与MRI辅助征象与肝细胞癌及恶性肿瘤的相关性:个体参与者数据Meta分析

LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis.
PubMed 文献 · Radiology · 2024-01-01

本个体参与者数据Meta分析纳入20项研究、3091个观察(2456例成人),评估LI-RADS CT/MRI辅助征象在调整主要征象后与肝细胞癌及恶性肿瘤的相关性。多数辅助征象按预期独立相关,其中非增强包膜与肝细胞癌关联最强,扩散受限与轻中度T2高信号与恶性肿瘤关联最强。

要点

  • 非增强包膜是与肝细胞癌关联最强的辅助征象(OR=3.50)。
  • 扩散受限(OR=14.45)和轻中度T2高信号(OR=10.18)与恶性肿瘤关联最强。
  • 平行血池强化(OR=0.07)和明显T2高信号(OR=0.18)与肝细胞癌负相关最强。

核心结论

  • 大多数LI-RADS辅助征象在调整主要征象后按预期独立与肝细胞癌、恶性肿瘤或良性相关。

研究设计与样本

  • 个体参与者数据Meta分析,检索Medline、Embase、Cochrane Central Register of Controlled Trials和Scopus(2014年1月至2022年1月),纳入20项研究共3091个观察(2456例成人参与者,平均年龄59岁±11[SD],1849例[75.3%]男性),采用一步法汇总个体参与者数据,以多变量logistic回归模型(随机截距处理研究水平和参与者水平的肝脏观察聚类)计算调整OR及95%CI。

诊断标准与关键数值

  • 非增强包膜与肝细胞癌的调整OR=3.50(95%CI:1.53,8.01)。
  • 扩散受限与恶性肿瘤的调整OR=14.45(95%CI:9.82,21.27)。
  • 轻中度T2高信号与恶性肿瘤的调整OR=10.18(95%CI:7.17,14.44)。
  • 平行血池强化与肝细胞癌的调整OR=0.07(95%CI:0.01,0.49)。
  • 明显T2高信号与肝细胞癌的调整OR=0.18(95%CI:0.07,0.45)。

局限性

  • 17项研究(85%)存在高偏倚风险。
  • 阈值增长因报告不频繁而被排除在多变量模型之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The independent contribution of each Liver Imaging Reporting and Data System (LI-RADS) CT or MRI ancillary feature (AF) has not been established. Purpose To evaluate the association of LI-RADS AFs with hepatocellular carcinoma (HCC) and malignancy while adjusting for LI-RADS major features through an individual participant data (IPD) meta-analysis. Materials and Methods Medline, Embase, Cochrane Central Register of Controlled Trials, and Scopus were searched from January 2014 to January 2022 for studies evaluating the diagnostic accuracy of CT and MRI for HCC using LI-RADS version 2014, 2017, or 2018. Using a one-step approach, IPD across studies were pooled. Adjusted odds ratios (ORs) and 95% CIs were derived from multivariable logistic regression models of each AF combined with major features except threshold growth (excluded because of infrequent reporting). Liver observation clustering was addressed at the study and participant levels through random intercepts. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2. Results Twenty studies comprising 3091 observations (2456 adult participants; mean age, 59 years ± 11 [SD]; 1849 [75.3%] men) were included. In total, 89% (eight of nine) of AFs favoring malignancy were associated with malignancy and/or HCC, 80% (four of five) of AFs favoring HCC were associated with HCC, and 57% (four of seven) of AFs favoring benignity were negatively associated with HCC and/or malignancy. Nonenhancing capsule (OR = 3.50 [95% CI: 1.53, 8.01]) had the strongest association with HCC. Diffusion restriction (OR = 14.45 [95% CI: 9.82, 21.27]) and mild-moderate T2 hyperintensity (OR = 10.18 [95% CI: 7.17, 14.44]) had the strongest association with malignancy. The strongest negative associations with HCC were parallels blood pool enhancement (OR = 0.07 [95% CI: 0.01, 0.49]) and marked T2 hyperintensity (OR = 0.18 [95% CI: 0.07, 0.45]). Seventeen studies (85%) had a high risk of bias. Conclusion Most LI-RADS AFs were independently associated with HCC, malignancy, or benignity as intended when adjusting for major features. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Crivellaro in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Dawit H, Lam E, McInnes MDF, et al. LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis. Radiology. 2024. PMID: 38376399. doi:10.1148/radiol.231501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。